Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (5,132,000)	$ (6,894,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	2,071,000	1,872,000
Common stock issued for services	291,000	367,000
Impairment, Long-Lived Asset, Held-for-Use, Total	197,000	342,000
Inventory reserve	158,000	0
Common stock issued for interest	0	16,000
Interest expense related to amortization of the discount on convertible notes payable	17,000	119,000
Loss on investment in South Korean joint venture	15,000	15,000
PPP forgiveness	(174,000)	(43,000)
Amortization and depreciation expense	45,000	20,000
Changes in assets and liabilities:
Accounts receivable	(551,000)	(29,000)
Inventories	(35,000)	36,000
Deferred revenue	(72,000)	41,000
Prepaid expenses and other assets	(90,000)	(57,000)
Right of use and lease liability, net	3,000	0
Deposit	105,000	79,000
Net cash used in operating activities	(2,762,000)	(3,937,000)
Cash flows from investing activities
Equipment purchases	(271,000)	(21,000)
Patent purchase	0	(13,000)
Net cash used in investing activities	(271,000)	(34,000)
Cash flows from financing activities
Proceeds from sale of common stock	3,617,000	4,882,000
Proceeds from warrant exercise	0	164,000
Proceeds from BioLargo stock option exercise	40,000	0
Repayment of note payable and line of credit	0	(828,000)
Repayment by Clyra on inventory line of credit	(26,000)	(37,000)
Proceeds from sale of preferred stock in Clyra Medical	225,000	0
Proceeds from Clyra Medical note payable	100,000	0
Net cash provided by financing activities	3,956,000	4,231,000
Net effect of foreign currency translation	(34,000)	(14,000)
Net change in cash	889,000	246,000
Cash at beginning of year	962,000	716,000
Cash at end of year	1,851,000	962,000
Supplemental disclosures of cash flow information
Interest	36,000	99,000
Income taxes	3,000	2,000
Short-term lease payments not included in lease liability	99,000	52,000
Non-cash investing and financing activities
Return of in-process research and development (Scion)	0	1,804,000
Cancellation of Clyra debt obligations and accounts payable (Scion)	0	(1,465,000)
Liability to Scion shareholders	0	(540,000)
Fair value of warrants issued with convertible notes and letter of credit	0	35,000
Conversion of convertible notes payable into common stock	0	328,000
Fair value of common stock issued to Lincoln Park as finance fee	240,000	0
Present value of new operating right of use and lease liability	443,000	186,000
Allocation of stock option expense within noncontrolling interest	1,287,000	1,149,000
Clyra Medical Common Stock [Member]
Cash flows from financing activities
Proceeds from sale of common stock	0	50,000
Entities, Excluding Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	382,000	47,000
Accounts payable and accrued expenses	382,000	47,000
Partially Owned Subsidiary [Member]
Changes in assets and liabilities:
Accounts payable and accrued expenses	8,000	132,000
Accounts payable and accrued expenses	$ 8,000	$ 132,000